The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PMVP | +33.33% | -95.33% | -45.78% | -96% |
| S&P | +17.45% | +75.43% | +11.88% | +104% |
PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$33.00K | 15.4% |
| Market Cap | $66.51M | -14.9% |
| Market Cap / Employee | $1.23M | 0.0% |
| Employees | 54 | 14.9% |
| Net Income | -$18,037.00K | 21.6% |
| EBITDA | -$19,209.00K | 23.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $37.98M | -7.1% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $435.00K | -48.1% |
| Short Term Debt | $403.00K | 14.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -50.51% | -24.0% |
| Return On Invested Capital | -23.62% | -1.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17,204.00K | -2.9% |
| Operating Free Cash Flow | -$17,189.00K | -3.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.32 | 0.34 | 0.53 | 0.55 | 38.68% |
| Price to Tangible Book Value | 0.32 | 0.34 | 0.53 | 0.55 | 38.68% |
| Enterprise Value to EBITDA | 4.77 | 3.77 | 2.41 | 2.37 | -33.74% |
| Return on Equity | -32.7% | -45.6% | -51.9% | -55.4% | 89.47% |
| Total Debt | $1.11M | $1.02M | $931.00K | $838.00K | -29.58% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
